Edwards' strategy focuses on three key elements: focusing solely on structural heart, solving large, urgent and very complex patient needs, and pursuing unique opportunities to innovate and lead. Strong demand for transcatheter valve therapies and expanding mitral and tricuspid portfolio drive double-digit quarterly growth. The company benefits from 70 years of valve innovation expertise and world-class clinical evidence supporting long-term product durability.
Cyborg Score Rationale
Edwards delivered double-digit fourth-quarter sales growth and expanding demand for structural heart therapies strengthens confidence in continued growth through 2026. The company maintains strong margin performance and robust cash position, though faces near-term pressure from operating expenses and tariff risks. Strategic product launches including SAPIEN M3 and expanding TAVR adoption provide meaningful growth catalysts.
Top Insights
TAVR sales reached $1.16 billion in Q4, up 12% year-over-year, driven by expanding treatment of severe aortic stenosis patients and continued adoption of the SAPIEN platform.
Transcatheter mitral/tricuspid therapies grew over 40%, driven by global adoption of PASCAL and EVOQUE systems plus recent U.S. FDA approval of the SAPIEN M3 mitral valve.
The company maintains gross profit margins of 78.1% for Q4 and expects adjusted gross margins between 78% and 79% for 2026.
CMS formally reopening the TAVR National Coverage Determination positions Edwards for a possible access catalyst, with initial draft expected around June 2026 and material impact anticipated in 2027 or later.
Named Competitors
MitraClip — Mitral valve repair system for degenerative and functional mitral regurgitation
Watchman — Left atrial appendage closure device for stroke prevention
CoreValve — Transcatheter aortic valve replacement system
Acurate neo2 — Next-generation transcatheter aortic valve system
Recent Developments
(December 2025) FDA approval of SAPIEN M3 mitral valve, the company's first transcatheter mitral valve replacement system
(February 2026) Q4 2025 results: 13.3% sales growth to $1.57B; 2026 guidance raised to 8-10% sales growth and $2.90-$3.05 adjusted EPS
(December 2025) Company reaffirmed 2026 strategy projecting TAVR sales of $4.6-$4.9B and TMTT revenue of $740-$780M with 35-45% growth
Open the full interactive Edwards Lifesciences Corporation report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.